Treatment of Midgut Neuroendocrine Tumors

February 10, 2017
Jonathan Strosberg, MD
Jonathan Strosberg, MD

This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.

In this video, Jonathan Strosberg, MD, of the Moffitt Cancer Center, discusses current options for the treatment of midgut neuroendocrine tumors; highlights results of the NETTER-1 trial, which showed improved progression-free survival with lutetium-177 (177Lu)–Dotatate in this patient population; and discusses the use of radionuclide therapy in other types of neuroendocrine tumors.

Results of the phase III NETTER-1 trial were recently published in the New England Journal of Medicine, showing that treatment of well-differentiated, metastatic midgut neuroendocrine tumors with 177Lu–Dotatate improved response rates (18% vs 3%) and improved the estimated rate of progression-free survival at 20 months (65.2% vs 10.8%).

Dr. Strosberg spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held last month in San Francisco.